{"product_id":"malignant-liver-tumors-isbn-9781405179768","title":"Malignant Liver Tumors","description":"This comprehensive and critical review of current and established treatment modalities for malignant liver tumors is designed to help you sort through the proliferation of competitive approaches and choose the best treatment options for your patient. Dr. Clavien and his contributors consider all the options – radiological, surgical, pharmaceutical, and emerging\/novel therapies – and help you find the best single or combined therapy.  \u003cp\u003eBuilding on the success of the previous edition, this extremely thorough revision:\u003c\/p\u003e \u003cul type=\"disc\"\u003e \u003cli\u003efeatures a new section on Guidelines for Liver Tumors, where you will find specific strategies for treating common liver malignancies; the guidelines were prepared by the Associate Editors and take into account national and international society guidelines\u003c\/li\u003e \u003cli\u003ereflects actual practice by taking a multidisciplinary approach, with contributions from international experts who have extensive experience with this patient population\u003c\/li\u003e \u003cli\u003eachieves comprehensive and balanced coverage by having each chapter reviewed by the Editor, Deputy Editor, two Associate Editors, and at least one external reviewer\u003c\/li\u003e \u003cli\u003eincludes 16 new chapters that cover liver anatomy, histologic changes in the liver, epidemiology and natural history of HCC, CCC and colorectal liver metastases, strategies of liver resection, and economic aspects as well as novel therapies\u003c\/li\u003e \u003cli\u003efacilitates the kind of daily interaction among hepatologists, hepatic surgeons, medical oncologists, radiotherapists, and interventional radiologists that is essential when treating patients with complex liver malignancies\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eIn 44 chapters organized into six major sections, the book covers the full range of liver tumors. The perfect blend of evidence and experience, \u003cb\u003eMalignant Liver Tumors: Current and Emerging Therapies, 3\u003csup\u003erd\u003c\/sup\u003e Edition,\u003c\/b\u003e illuminates the path to better patient care.\u003c\/p\u003e  Contributors, vii  \u003cp\u003ePreface, xi\u003c\/p\u003e \u003cp\u003eAcknowledgments, xiii\u003c\/p\u003e \u003cp\u003eAbbreviations, xiv\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 1 Introduction, 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 From Promethean to Modern Times, 3\u003cbr\u003e \u003ci\u003eKuno Lehmann, Stefan Breitenstein, and Pierre-Alain Clavien\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Hepatic Anatomy and Terminology, 11\u003cbr\u003e \u003ci\u003eSteven M. Strasberg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 2 Epidemiology and Diagnosis, 27\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 29\u003cbr\u003e \u003ci\u003eChung-Mau Lo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Histology and Pathology of Normal and Diseased Liver, 30\u003cbr\u003e \u003ci\u003eValérie Paradis and Achim Weber\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Pathology of Primary and Secondary Malignant Liver Tumors, 40\u003cbr\u003e \u003ci\u003eKay Washington\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Epidemiology, Etiology, and Natural History of Hepatocellular Carcinoma, 52\u003cbr\u003e \u003ci\u003eWei-Chen Lee and Miin-Fu Chen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Epidemiology, Etiology, and Natural History of Cholangiocarcinoma, 56\u003cbr\u003e \u003ci\u003ePeter Neuhaus, Ulf P. Neumann, and Daniel Seehofer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Epidemiology, Etiology, and Natural History of Colorectal Liver Metastases, 64\u003cbr\u003e \u003ci\u003eRobert J. Porte\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Tumor Markers in Primary and Secondary Liver Tumors, 69\u003cbr\u003e \u003ci\u003eKetsia B. Pierre and Ravi S. Chari\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Modalities for Imaging Liver Tumors, 76\u003cbr\u003e \u003ci\u003eDominik Weishaupt and Thomas F. Hany\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 3 Systemic and Regional Therapies, 103\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 105\u003cbr\u003e \u003ci\u003eRavi S. Chari\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Systemic Treatment of Hepatobiliary Tumors, 107\u003cbr\u003e \u003ci\u003ePanagiotis Samaras, Michael A. Morse, and Bernhard C. Pestalozzi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 External Beam Radiation Therapy for Liver Tumors, 122\u003cbr\u003e \u003ci\u003eRakesh Reddy and A. Bapsi Chakravarthy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Internal Radiation Therapy for Liver Tumors, 131\u003cbr\u003e \u003ci\u003eAhsun Riaz, Laura Kulik, Michael Abecassis, and Riad Salem\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Transarterial Embolization for Patients with Hepatocellular Carcinoma, 139\u003cbr\u003e \u003ci\u003eJordi Bruix, Carmen Ayuso, and Maria I. Real\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Selective Continuous Intra-arterial Chemotherapy for Liver Tumors, 151\u003cbr\u003e \u003ci\u003eFidel D. Huitzil-Melendez, Stefan Breitenstein, and Nancy Kemeny\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion, 164\u003cbr\u003e \u003ci\u003eCharles K. Heller, III, James F. Pingpank, and Steven K. Libutti\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 4 Resection, Ablation or Transplantation for Liver Tumors, 173\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 175\u003cbr\u003e \u003ci\u003eJean-Nicolas Vauthey and Tadatoshi Takayama\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Liver Resection of Primary Tumors: Hepatocellular Carcinoma, Cholangiocarcinoma, and Gallbladder Cancer, 177\u003cbr\u003e \u003ci\u003eTadatoshi Takayama and Masatoshi Makuuchi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Liver Resection of Colorectal Liver Metastases, 192\u003cbr\u003e \u003ci\u003eDaria Zorzi, Yun Shin Chun, and Jean-Nicolas Vauthey\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Laparoscopic Liver Resection, 203\u003cbr\u003e \u003ci\u003eLuca Viganò and Daniel Cherqui\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Repeat Resection for Liver Tumors, 216\u003cbr\u003e \u003ci\u003eMickael Lesurtel and Henrik Petrowsky\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Cryoablation of Liver Tumors, 227\u003cbr\u003e \u003ci\u003eSivakumar Gananadha and David L. Morris\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Thermal Ablation of Liver Tumors by Radiofrequency, Microwave, and Laser Therapy, 244\u003cbr\u003e \u003ci\u003eM. B. Majella Doyle and David C. Linehan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Ethanol and Other Percutaneous Injection Modalities in the Treatment of Liver Tumors, 266\u003cbr\u003e \u003ci\u003eMichael A. Heneghan and Andrew D. Yeoman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Transplantation for Liver Tumors, 281\u003cbr\u003e \u003ci\u003eFrançois Durand, Claire Francoz, and Jacques Belghiti\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Preventing Recurrence of Hepatocellular Carcinoma after Curative Resection, 296\u003cbr\u003e \u003ci\u003eStefan Breitenstein, Dimitris Dimitroulis, and Beat Müllhaupt\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 5 Guidelines for Liver Tumor Treatment, 305\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 307\u003cbr\u003e \u003ci\u003eStefan Breitenstein and Pierre-Alain Clavien\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Strategies for Safer Liver Surgery, 308\u003cbr\u003e \u003ci\u003ePhilipp Dutkowski, Olivier de Rougemont, and Pierre-Alain Clavien\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Hepatocellular Carcinoma, 317\u003cbr\u003e \u003ci\u003eTadatoshi Takayama\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 Cholangiocarcinoma, 324\u003cbr\u003e \u003ci\u003eJacques Belghiti and Charles B. Rosen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Gallbladder Cancer, 333\u003cbr\u003e \u003ci\u003eJuan Hepp and Chung-Mau Lo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Colorectal Liver Metastases, 342\u003cbr\u003e \u003ci\u003ePhuong L. Doan, Jean-Nicolas Vauthey, Martin Palavecino, and Michael A. Morse\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 6 Emerging Therapies, 347\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 349\u003cbr\u003e \u003ci\u003eMichael A. Morse and Josep M. Llovet\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 Viral-Based Therapies for Primary and Secondary Liver Cancer, 352\u003cbr\u003e \u003ci\u003eMenghua Dai, Lorena Gonzalez, and Yuman Fong\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e31 Signaling Pathways and Rationale for Molecular Therapies in Hepatocellular Carcinoma, 368\u003cbr\u003e \u003ci\u003eAugusto Villanueva, Clara Alsinet, and Josep M. Llovet\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32 Novel Therapies Targeted at Signal Transduction in Liver Tumors, 382\u003cbr\u003e \u003ci\u003eFidel D. Huitzil-Melendez, Ghassan K. Abou-Alfa, and Michael A. Morse\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e33 Induction of Apoptosis in Liver Tumors, 393\u003cbr\u003e \u003ci\u003eMarkus Selzner and Pierre-Alain Clavien\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e34 Antiangiogenic Agents for Liver Tumors, 400\u003cbr\u003e \u003ci\u003eMathijs Vogten, Emile E. Voest, and Inne H.M. Borel Rinkes\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e35 Integrative Oncology: Alternative and Complementary Treatments, 414\u003cbr\u003e \u003ci\u003eBarrie R. Cassileth and Jyothirmai Gubili\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 7 Special Tumors, Population, and Special Considerations, 421\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 423\u003cbr\u003e \u003ci\u003eStefan Breitenstein and Pierre-Alain Clavien\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e36 Liver Metastases from Endocrine Tumors, 424\u003cbr\u003e \u003ci\u003eClayton D. Knox and C. Wright Pinson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e37 Uncommon Primary and Metastatic Liver Tumors, 439\u003cbr\u003e \u003ci\u003eStefan Breitenstein, Ashraf Mohammad El-Badry, and Pierre-Alain Clavien\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e38 Liver Tumors in Special Populations, 454\u003cbr\u003e \u003ci\u003eTadahiro Uemura, Akhtar Khan, and Zakiyah Kadry\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e39 Malignant Liver Tumors in Children, 475\u003cbr\u003e \u003ci\u003eXavier Rogiers and Ruth De Bruyne\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e40 Liver Tumors in Asia, 487\u003cbr\u003e \u003ci\u003eNorihiro Kokudo, Sumihito Tamura, and Masatoshi Makuuchi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e41 Liver Tumors in South America, 500\u003cbr\u003e \u003ci\u003eLucas McCormack and Eduardo de Santibañes\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e42 Liver Tumors in Africa, 509\u003cbr\u003e \u003ci\u003eMichael C. Kew\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e43 Anesthetic Management of Liver Surgery, 519\u003cbr\u003e \u003ci\u003eMarco P. Zalunardo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e44 Qualitative and Economic Aspects of Liver Surgery, 531\u003cbr\u003e \u003ci\u003eRené Vonlanthen, Ksenija Slankamenac, and Christian Ernst\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex, 539\u003c\/p\u003e  \u003cp\u003e“This book is a worthy update. A significant amount of material has been added, including the new section. It definitely justifies replacing the old edition and will be a valuable resource for physicians of all disciplines involved in the care of these patients.”  (\u003ci\u003eDoody’s\u003c\/i\u003e, 23 March 2012)\u003c\/p\u003e \u003cp\u003e\"The third edition of Malignant Liver Tumors is well written with broad coverage of primary and metastatic liver tumors with a particular emphasis on current and emerging treatment. Consisting of up-to-date and comprehensive reviews on management of hepatic neoplasms, this book will not only be instructive to liver surgeons, trainees, and fellows, but also be valuable to hepatologists, oncologists, and interventional radiologists who form the multidisciplinary team to manage patients with these tumors.\" (Gastroenterological, 1 March 2011)\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e  \u003cb\u003eEditor-in-Chief:\u003cbr\u003e Pierre-Alain Clavien\u003c\/b\u003e\u003cbr\u003e Department of Visceral and Transplant Surgery, University Hospital Zurich, Switzerland\u003cbr\u003e   \u003cp\u003e\u003cb\u003eAssociate Editors:\u003cbr\u003e Tadatoshi Takayama\u003c\/b\u003e, Second Department of Surgery, Faculty of Medicine, University of Tokyo, Japan\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003eCM Lo\u003c\/b\u003e, Liver Transplant Centre, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003eR. Chari\u003c\/b\u003e, Associate Professor of Surgery and Cancer Biology, Division Chief of Hepatobillary Surgery and Liver Transplantation, Staff Surgeon, Veterans Affairs Medical Center, Vanderbilt University Medical Center, Nashville, USA\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003eM. Morse\u003c\/b\u003e, Associate Professor, Duke University Medical School, Durham, USA\u003cbr\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003eJ. Llovet\u003c\/b\u003e, Barcelona-Clínic Liver Cancer Group, Liver Unit, Institut d'Investigacions Biomédiques August Pi I Sunyer, Hospital Clínic, University of Barcelona, Catalonia, Spain\u003c\/p\u003e  This comprehensive and critical review of current and established treatment modalities for malignant liver tumors is designed to help you sort through the proliferation of competitive approaches and choose the best treatment options for your patient. Dr. Clavien and his contributors consider all the options – radiological, surgical, pharmaceutical, and emerging\/novel therapies – and help you find the best single or combined therapy.  \u003cp\u003eBuilding on the success of the previous edition, this extremely thorough revision:\u003c\/p\u003e \u003cul type=\"disc\"\u003e \u003cli\u003efeatures a new section on Guidelines for Liver Tumors, where you will find specific strategies for treating common liver malignancies; the guidelines were prepared by the Associate Editors and take into account national and international society guidelines\u003c\/li\u003e \u003cli\u003ereflects actual practice by taking a multidisciplinary approach, with contributions from international experts who have extensive experience with this patient population\u003c\/li\u003e \u003cli\u003eachieves comprehensive and balanced coverage by having each chapter reviewed by the Editor, Deputy Editor, two Associate Editors, and at least one external reviewer\u003c\/li\u003e \u003cli\u003eincludes 16 new chapters that cover liver anatomy, histologic changes in the liver, epidemiology and natural history of HCC, CCC and colorectal liver metastases, strategies of liver resection, and economic aspects as well as novel therapies\u003c\/li\u003e \u003cli\u003efacilitates the kind of daily interaction among hepatologists, hepatic surgeons, medical oncologists, radiotherapists, and interventional radiologists that is essential when treating patients with complex liver malignancies\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eIn 44 chapters organized into six major sections, the book covers the full range of liver tumors. The perfect blend of evidence and experience, \u003cb\u003eMalignant Liver Tumors: Current and Emerging Therapies, 3\u003csup\u003erd\u003c\/sup\u003e Edition,\u003c\/b\u003e illuminates the path to better patient care.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989558247653,"sku":"NP9781405179768","price":352.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781405179768.jpg?v=1761784590","url":"https:\/\/k12savings.com\/products\/malignant-liver-tumors-isbn-9781405179768","provider":"K12savings","version":"1.0","type":"link"}